Know Cancer

or
forgot password

Phase I Trial of AVD Plus Lenalidomide (Revlimid) in Elderly Intermediate or Advanced Stage Hodgkin Lymphoma Patients


Phase 1
60 Years
75 Years
Open (Enrolling)
Both
Hodgkin Lymphoma

Thank you

Trial Information

Phase I Trial of AVD Plus Lenalidomide (Revlimid) in Elderly Intermediate or Advanced Stage Hodgkin Lymphoma Patients


Inclusion Criteria:



- Hodgkin Lymphoma, intermediate or advanced stage

- Age >60 and <75 years

- ECOG 2 or better

- No major organ dysfunction

- Ability to take aspirin or LMW Heparin

Exclusion Criteria:

- HL as composite lymphoma

- Prior use of lenalidomide

- Prior use of chemo- or radiotherapy

Type of Study:

Interventional

Study Design:

Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Dose limiting toxicities (DLT)

Safety Issue:

Yes

Principal Investigator

Andreas Engert, Prof.

Investigator Role:

Principal Investigator

Investigator Affiliation:

University of Cologne

Authority:

Germany: Federal Institute for Drugs and Medical Devices

Study ID:

AVD-Rev

NCT ID:

NCT01056679

Start Date:

April 2010

Completion Date:

April 2014

Related Keywords:

  • Hodgkin Lymphoma
  • Hodgkin Disease
  • Lymphoma

Name

Location